Ofatumumab for treating relapsing multiple sclerosis – guidance (TA699)

NICE recommend ofatumumab an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

Source:

National Institute for Health and Care Excellence